The 19 most recent market catalysts affecting $RHHBY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 75
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche received FDA approval for Wilserdly (giredestrant), its new oral breast cancer treatment, for advanced or metastatic cases in combination with Novartis's Afinitor. This is a …
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 65
Roche Receives FDA De Novo Authorization for Mass Spectrometry Platform
Roche Diagnostics received FDA De Novo authorization for its cobas® pro i 601 platform, a significant regulatory milestone. This authorization allows Roche to market a new automate…
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 55
Roche Diagnostics Makes Endotrophin Research Prototype Assay Available at Nordic Bioscience
Roche Diagnostics has announced the availability of its Endotrophin (ETP) research prototype assay at Nordic Bioscience. This is a significant step as it provides researchers with …
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 65
Roche Receives FDA Approval for Gazyva in Primary Membranous Nephropathy
Roche, through its Genentech subsidiary, secured FDA approval for Gazyva (obinutuzumab) to treat primary membranous nephropathy. This is significant because it expands the drug's u…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 65
Health Canada Approves Ocrevus for Pediatric Relapsing-Remitting Multiple Sclerosis
Health Canada's approval of Ocrevus for pediatric relapsing-remitting multiple sclerosis (RRMS) is a significant regulatory win for Roche. This expands the drug's addressable marke…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
Roche Receives FDA 510(k) Clearance for Cobas Eplex Respiratory Pathogen Panel 3
Roche announced it received FDA 510(k) clearance for its cobas eplex respiratory pathogen panel 3. This is a positive development for Roche as it expands its diagnostic product off…
Oct 19, 2026
Corporate Catalyst
Bearish
Impact 75
Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts
Roche's decision to halt future investments in Germany is a direct response to the GKV Contribution Rate Stabilization Act, which significantly increases mandatory drug rebates. Th…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
Roche’s Genentech To Present Pivotal Lung And Breast Cancer Data At ESMO 2026, Highlighting Divarasib Superiority Over Standard Of Care And Giredestrant Efficacy Gains Without Tolerability Or Quality-Of-Life Compromise
Roche's Genentech is set to present compelling Phase III clinical trial results for three of its oncology drugs at the ESMO 2026 conference. The key highlights include divarasib de…
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 75
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
Roche Holdings AG announced FDA approval for Enspryng (satralizumab) for thyroid eye disease (TED), marking it as the first and only at-home subcutaneous treatment for this conditi…
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Approves Roche’s Enspryng For Adults With Thyroid Eye Disease, First At-Home Subcutaneous Option; SatraGO-2 Proptosis Response 52.9% Vs 23.4% Placebo, SatraGO-1 Missed Primary Endpoint
Roche announced FDA approval for Enspryng (satralizumab) for adults with Thyroid Eye Disease (TED). This is a significant development as Enspryng is the first at-home subcutaneous …
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks
The FDA's acceptance of Genentech's Biologics License Application (BLA) for vamikibart is a crucial regulatory milestone. This indicates that the FDA has deemed the application com…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
Roche Wins FDA Nod For Tecentriq Combination In Adjuvant Stage III DMMR Colon Cancer As 36-Month Disease-Free Survival Reaches 86% Versus 76% With Chemotherapy Alone In ATOMIC Trial
Roche's Tecentriq has secured FDA approval for adjuvant treatment of Stage III dMMR colon cancer, a significant milestone. This approval is based on compelling data from the ATOMIC…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 65
Roche's Vabysmo Lifts Vision By 4.6 Letters In Untreated nAMD Eyes And 8.2 In DME After 12 Months In Real-World VOYAGER Data Presented At EURETINA
Roche's 8-K filing highlights compelling real-world data for its blockbuster eye drug, Vabysmo, from the large VOYAGER study. The reported vision improvements and anatomical drying…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 85
Genentech's Giredestrant Plus Everolimus Cuts Risk Of Progression Or Death 44% In ITT And 62% In ESR1-Mutated ER-Positive Advanced Breast Cancer In Phase III EvERA; FDA Goal Dates Are Dec. 18 For Advanced Disease And Nov. 30 For Early-Stage Disease
Genentech, a subsidiary of Roche (RHHBY, ROG.SW), announced highly positive Phase III results for its drug Giredestrant in combination with everolimus for ER-positive advanced brea…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide
Roche announced that the FDA has accepted its New Drug Application (NDA) for fenebrutinib for priority review in relapsing and primary progressive multiple sclerosis (MS). This is …
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Roche Says Phase III CELESTIMO Study Meets Primary Endpoint With Clinically Meaningful Reduction In Disease Progression Risk For Follicular Lymphoma Patients
Roche announced that its Phase III CELESTIMO study, evaluating a Lunsumio-based regimen for follicular lymphoma, successfully met its primary endpoint at an interim analysis. This …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
FDA Grants Priority Review To Genentech's Enspryng For MOGAD, Phase III METEOROID Study Showed 68% Reduction In Relapse Risk Versus Placebo
Genentech's Enspryng receiving FDA Priority Review for MOGAD is a significant development. This designation accelerates the review process for drugs that, if approved, would provid…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 65
Roche's Vabysmo Shows Sustained Two-Year Results In SALWEEN Study, With 61% Of PCV Patients Achieving Extended 20-Week Dosing
Roche announced positive two-year results from its SALWEEN study for Vabysmo, a drug treating polypoidal choroidal vasculopathy (PCV), an aggressive form of nAMD. The study showed …
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus
Roche's Gazyva/Gazyvaro has been granted FDA Priority Review for primary membranous nephropathy (pMN), a chronic autoimmune disease with no currently approved therapies. This is a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.